Eterna Therapeutics Inc. (ERNA)
After hours:
| Previous close | 2.1600 |
| Open | 2.1200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.0201 - 2.1200 |
| 52-week range | 0.8400 - 2.9900 |
| Volume | |
| Avg. volume | 8,411 |
| Market cap | 10.929M |
| Beta (5Y monthly) | 8.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in vivo persistence, and enhancing the effector function of the cellsThe presentation is on Saturday, May 11th, 2024 CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc
- GlobeNewswire
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a preclinical-stage biopharmaceutical company, committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announces the appointment of Mahendra Rao, PhD, to its scientific advisory board. “We’re honored to have Dr. Mahendra Rao join our Scientific Advisory Board,” said Sanjeev Luther, President and CEO of Eterna.
- GlobeNewswire
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus
Eterna reports the development of an mRNA-engineered iPSC line developed using UltraSlice™ to express a B2M-HLA-E fusion transgene in lieu of the endogenous B2M gene product to mimic native B2M expressionThe cells may prove useful for the rapid development of therapeutics with the potential for increased efficacy and safety owing to the immune-evasive nature of the cellsThe poster presentation is on Friday, May 10th 2024 CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc.
